Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients.
Alexander V LavrovEkaterina Yu ChelyshevaElmira P AdilgereevaOleg A ShukhovSvetlana A SmirnikhinaKonstantin S Kochergin-NikitskyValentina D YakushinaGrigory A TsaurSergey V MordanovAnna G TurkinaSergey I KutsevPublished in: BMC medical genomics (2019)
Using modern high-throughput methods such as whole-exome sequencing, transcriptome and miRNA analysis, we could not find reliable molecular markers for early prediction of TKI efficiency in Ph+ CML patients.
Keyphrases
- end stage renal disease
- high throughput
- ejection fraction
- newly diagnosed
- single cell
- chronic kidney disease
- gene expression
- prognostic factors
- genome wide
- peritoneal dialysis
- rna seq
- chronic myeloid leukemia
- dna methylation
- advanced non small cell lung cancer
- patient reported outcomes
- single molecule
- epidermal growth factor receptor